[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

<p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ratib Osman [verfasserIn] Dipasquale Giovanna [verfasserIn] Nouet Philippe [verfasserIn] Rouzaud Michel [verfasserIn] Haller Guy [verfasserIn] Casanova Nathalie [verfasserIn] Buchegger Franz [verfasserIn] Zilli Thomas [verfasserIn] Weber Damien C [verfasserIn] Zaidi Habib [verfasserIn] Vees Hansjorg [verfasserIn] Miralbell Raymond [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2008

Übergeordnetes Werk:	In: Radiation Oncology - BMC, 2006, 3(2008), 1, p 44
Übergeordnetes Werk:	volume:3 ; year:2008 ; number:1, p 44

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1186/1748-717X-3-44

Katalog-ID:	DOAJ038556936

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ038556936
003	DE-627
005	20230308022655.0
007	cr uuu---uuuuu
008	230227s2008 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/1748-717X-3-44 \|2 doi
035			\|a (DE-627)DOAJ038556936
035			\|a (DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R895-920
050		0	\|a RC254-282
100	0		\|a Ratib Osman \|e verfasserin \|4 aut
245	1	0	\|a [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
264		1	\|c 2008
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p<
653		0	\|a Medical physics. Medical radiology. Nuclear medicine
653		0	\|a Neoplasms. Tumors. Oncology. Including cancer and carcinogens
700	0		\|a Dipasquale Giovanna \|e verfasserin \|4 aut
700	0		\|a Nouet Philippe \|e verfasserin \|4 aut
700	0		\|a Rouzaud Michel \|e verfasserin \|4 aut
700	0		\|a Haller Guy \|e verfasserin \|4 aut
700	0		\|a Casanova Nathalie \|e verfasserin \|4 aut
700	0		\|a Buchegger Franz \|e verfasserin \|4 aut
700	0		\|a Zilli Thomas \|e verfasserin \|4 aut
700	0		\|a Weber Damien C \|e verfasserin \|4 aut
700	0		\|a Zaidi Habib \|e verfasserin \|4 aut
700	0		\|a Vees Hansjorg \|e verfasserin \|4 aut
700	0		\|a Miralbell Raymond \|e verfasserin \|4 aut
773	0	8	\|i In \|t Radiation Oncology \|d BMC, 2006 \|g 3(2008), 1, p 44 \|w (DE-627)508725739 \|w (DE-600)2224965-5 \|x 1748717X \|7 nnns
773	1	8	\|g volume:3 \|g year:2008 \|g number:1, p 44
856	4	0	\|u https://doi.org/10.1186/1748-717X-3-44 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf \|z kostenfrei
856	4	0	\|u http://www.ro-journal.com/content/3/1/44 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1748-717X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 3 \|j 2008 \|e 1, p 44

Indexfelder

author_variant	r o ro d g dg n p np r m rm h g hg c n cn b f bf z t zt w d c wdc z h zh v h vh m r mr
matchkey_str	article:1748717X:2008----::8furehlyoieoirnmsinoorpyuddaite
hierarchy_sort_str	2008
callnumber-subject-code	R
publishDate	2008
allfields	10.1186/1748-717X-3-44 doi (DE-627)DOAJ038556936 (DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Dipasquale Giovanna verfasserin aut Nouet Philippe verfasserin aut Rouzaud Michel verfasserin aut Haller Guy verfasserin aut Casanova Nathalie verfasserin aut Buchegger Franz verfasserin aut Zilli Thomas verfasserin aut Weber Damien C verfasserin aut Zaidi Habib verfasserin aut Vees Hansjorg verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 3(2008), 1, p 44 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:3 year:2008 number:1, p 44 https://doi.org/10.1186/1748-717X-3-44 kostenfrei https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf kostenfrei http://www.ro-journal.com/content/3/1/44 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1, p 44
spelling	10.1186/1748-717X-3-44 doi (DE-627)DOAJ038556936 (DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Dipasquale Giovanna verfasserin aut Nouet Philippe verfasserin aut Rouzaud Michel verfasserin aut Haller Guy verfasserin aut Casanova Nathalie verfasserin aut Buchegger Franz verfasserin aut Zilli Thomas verfasserin aut Weber Damien C verfasserin aut Zaidi Habib verfasserin aut Vees Hansjorg verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 3(2008), 1, p 44 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:3 year:2008 number:1, p 44 https://doi.org/10.1186/1748-717X-3-44 kostenfrei https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf kostenfrei http://www.ro-journal.com/content/3/1/44 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1, p 44
allfields_unstemmed	10.1186/1748-717X-3-44 doi (DE-627)DOAJ038556936 (DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Dipasquale Giovanna verfasserin aut Nouet Philippe verfasserin aut Rouzaud Michel verfasserin aut Haller Guy verfasserin aut Casanova Nathalie verfasserin aut Buchegger Franz verfasserin aut Zilli Thomas verfasserin aut Weber Damien C verfasserin aut Zaidi Habib verfasserin aut Vees Hansjorg verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 3(2008), 1, p 44 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:3 year:2008 number:1, p 44 https://doi.org/10.1186/1748-717X-3-44 kostenfrei https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf kostenfrei http://www.ro-journal.com/content/3/1/44 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1, p 44
allfieldsGer	10.1186/1748-717X-3-44 doi (DE-627)DOAJ038556936 (DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Dipasquale Giovanna verfasserin aut Nouet Philippe verfasserin aut Rouzaud Michel verfasserin aut Haller Guy verfasserin aut Casanova Nathalie verfasserin aut Buchegger Franz verfasserin aut Zilli Thomas verfasserin aut Weber Damien C verfasserin aut Zaidi Habib verfasserin aut Vees Hansjorg verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 3(2008), 1, p 44 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:3 year:2008 number:1, p 44 https://doi.org/10.1186/1748-717X-3-44 kostenfrei https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf kostenfrei http://www.ro-journal.com/content/3/1/44 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1, p 44
allfieldsSound	10.1186/1748-717X-3-44 doi (DE-627)DOAJ038556936 (DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf DE-627 ger DE-627 rakwb eng R895-920 RC254-282 Ratib Osman verfasserin aut [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma 2008 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p< Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens Dipasquale Giovanna verfasserin aut Nouet Philippe verfasserin aut Rouzaud Michel verfasserin aut Haller Guy verfasserin aut Casanova Nathalie verfasserin aut Buchegger Franz verfasserin aut Zilli Thomas verfasserin aut Weber Damien C verfasserin aut Zaidi Habib verfasserin aut Vees Hansjorg verfasserin aut Miralbell Raymond verfasserin aut In Radiation Oncology BMC, 2006 3(2008), 1, p 44 (DE-627)508725739 (DE-600)2224965-5 1748717X nnns volume:3 year:2008 number:1, p 44 https://doi.org/10.1186/1748-717X-3-44 kostenfrei https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf kostenfrei http://www.ro-journal.com/content/3/1/44 kostenfrei https://doaj.org/toc/1748-717X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 3 2008 1, p 44
language	English
source	In Radiation Oncology 3(2008), 1, p 44 volume:3 year:2008 number:1, p 44
sourceStr	In Radiation Oncology 3(2008), 1, p 44 volume:3 year:2008 number:1, p 44
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Medical physics. Medical radiology. Nuclear medicine Neoplasms. Tumors. Oncology. Including cancer and carcinogens
isfreeaccess_bool	true
container_title	Radiation Oncology
authorswithroles_txt_mv	Ratib Osman @@aut@@ Dipasquale Giovanna @@aut@@ Nouet Philippe @@aut@@ Rouzaud Michel @@aut@@ Haller Guy @@aut@@ Casanova Nathalie @@aut@@ Buchegger Franz @@aut@@ Zilli Thomas @@aut@@ Weber Damien C @@aut@@ Zaidi Habib @@aut@@ Vees Hansjorg @@aut@@ Miralbell Raymond @@aut@@
publishDateDaySort_date	2008-01-01T00:00:00Z
hierarchy_top_id	508725739
id	DOAJ038556936
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ038556936</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308022655.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1748-717X-3-44</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ038556936</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R895-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ratib Osman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical physics. Medical radiology. Nuclear medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dipasquale Giovanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nouet Philippe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rouzaud Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haller Guy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Casanova Nathalie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Buchegger Franz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zilli Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weber Damien C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zaidi Habib</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vees Hansjorg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miralbell Raymond</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Radiation Oncology</subfield><subfield code="d">BMC, 2006</subfield><subfield code="g">3(2008), 1, p 44</subfield><subfield code="w">(DE-627)508725739</subfield><subfield code="w">(DE-600)2224965-5</subfield><subfield code="x">1748717X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1, p 44</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1748-717X-3-44</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ro-journal.com/content/3/1/44</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1748-717X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2008</subfield><subfield code="e">1, p 44</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Ratib Osman
spellingShingle	Ratib Osman misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
authorStr	Ratib Osman
ppnlink_with_tag_str_mv	@@773@@(DE-627)508725739
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R895-920
illustrated	Not Illustrated
issn	1748717X
topic_title	R895-920 RC254-282 [(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
topic	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_unstemmed	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
topic_browse	misc R895-920 misc RC254-282 misc Medical physics. Medical radiology. Nuclear medicine misc Neoplasms. Tumors. Oncology. Including cancer and carcinogens
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Radiation Oncology
hierarchy_parent_id	508725739
hierarchy_top_title	Radiation Oncology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)508725739 (DE-600)2224965-5
title	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
ctrlnum	(DE-627)DOAJ038556936 (DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf
title_full	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
author_sort	Ratib Osman
journal	Radiation Oncology
journalStr	Radiation Oncology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2008
contenttype_str_mv	txt
author_browse	Ratib Osman Dipasquale Giovanna Nouet Philippe Rouzaud Michel Haller Guy Casanova Nathalie Buchegger Franz Zilli Thomas Weber Damien C Zaidi Habib Vees Hansjorg Miralbell Raymond
container_volume	3
class	R895-920 RC254-282
format_se	Elektronische Aufsätze
author-letter	Ratib Osman
doi_str_mv	10.1186/1748-717X-3-44
author2-role	verfasserin
title_sort	[(18)f]fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
callnumber	R895-920
title_auth	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
abstract	<p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p<
abstractGer	<p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p<
abstract_unstemmed	<p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2108 GBV_ILN_2111 GBV_ILN_2119 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1, p 44
title_short	[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma
url	https://doi.org/10.1186/1748-717X-3-44 https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf http://www.ro-journal.com/content/3/1/44 https://doaj.org/toc/1748-717X
remote_bool	true
author2	Dipasquale Giovanna Nouet Philippe Rouzaud Michel Haller Guy Casanova Nathalie Buchegger Franz Zilli Thomas Weber Damien C Zaidi Habib Vees Hansjorg Miralbell Raymond
author2Str	Dipasquale Giovanna Nouet Philippe Rouzaud Michel Haller Guy Casanova Nathalie Buchegger Franz Zilli Thomas Weber Damien C Zaidi Habib Vees Hansjorg Miralbell Raymond
ppnlink	508725739
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/1748-717X-3-44
callnumber-a	R895-920
up_date	2024-07-03T18:36:03.694Z
_version_	1803584026649296896
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ038556936</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308022655.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2008 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1748-717X-3-44</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ038556936</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ37bb3e65534c4f55bf8529bd265e01cf</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R895-920</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC254-282</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ratib Osman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2008</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<To compare morphological gross tumor volumes (GTVs), defined as pre- and postoperative gadolinium enhancement on T<sub<1</sub<-weighted magnetic resonance imaging to biological tumor volumes (BTVs), defined by the uptake of <sup<18</sup<F fluoroethyltyrosine (FET) for the radiotherapy planning of high-grade glioma, using a dedicated positron emission tomography (PET)-CT scanner equipped with three triangulation lasers for patient positioning.</p< <p<Methods</p< <p<Nineteen patients with malignant glioma were included into a prospective protocol using FET PET-CT for radiotherapy planning. To be eligible, patients had to present with residual disease after surgery. Planning was performed using the clinical target volume (CTV = GTV ∪ BTV) and planning target volume (PTV = CTV + 20 mm). First, the interrater reliability for BTV delineation was assessed among three observers. Second, the BTV and GTV were quantified and compared. Finally, the geometrical relationships between GTV and BTV were assessed.</p< <p<Results</p< <p<Interrater agreement for BTV delineation was excellent (intraclass correlation coefficient 0.9). Although, BTVs and GTVs were not significantly different (<it<p </it<= 0.9), CTVs (mean 57.8 ± 30.4 cm<sup<3</sup<) were significantly larger than BTVs (mean 42.1 ± 24.4 cm<sup<3</sup<; <it<p </it<< 0.01) or GTVs (mean 38.7 ± 25.7 cm<sup<3</sup<; <it<p </it<< 0.01). In 13 (68%) and 6 (32%) of 19 patients, FET uptake extended ≥ 10 and 20 mm from the margin of the gadolinium enhancement.</p< <p<Conclusion</p< <p<Using FET, the interrater reliability had excellent agreement for BTV delineation. With FET PET-CT planning, the size and geometrical location of GTVs and BTVs differed in a majority of patients.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medical physics. Medical radiology. Nuclear medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dipasquale Giovanna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nouet Philippe</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Rouzaud Michel</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Haller Guy</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Casanova Nathalie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Buchegger Franz</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zilli Thomas</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Weber Damien C</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zaidi Habib</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vees Hansjorg</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Miralbell Raymond</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Radiation Oncology</subfield><subfield code="d">BMC, 2006</subfield><subfield code="g">3(2008), 1, p 44</subfield><subfield code="w">(DE-627)508725739</subfield><subfield code="w">(DE-600)2224965-5</subfield><subfield code="x">1748717X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:3</subfield><subfield code="g">year:2008</subfield><subfield code="g">number:1, p 44</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1748-717X-3-44</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/37bb3e65534c4f55bf8529bd265e01cf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ro-journal.com/content/3/1/44</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1748-717X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">3</subfield><subfield code="j">2008</subfield><subfield code="e">1, p 44</subfield></datafield></record></collection>
score	7.401078

Nicht das Richtige dabei?

Schreiben Sie uns!

[(18)F]Fluoroethyltyrosine- positron emission tomography-guided radiotherapy for high-grade glioma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?